The King’s MND Care and Research Centre was the first specialist centre for MND / ALS to have been established in the UK, and is a partnership between King’s College Hospital NHS Foundation Trust, which hosts the King’s Motor Nerve Clinic, and King’s College London, home to our world-class research group. The Centre is part-funded by the Motor Neurone Disease Association. Our aim is to find a cure for ALS, and improve quality of life for patients and their families.
An award-winning, highly specialized multidisciplinary clinical team oversees care for patients and families in close communication with local and community health professionals.
The clinic is very research active, and participates in studies of ALS worldwide with an ethos of collaboration and data sharing. We helped find the only current disease-modifying treatment for ALS, Riluzole, and our staff have been recognized with national and international awards and prizes, including two current and one previous consultant each awarded the prestigious Sheila Essey Award from the American Academy of Neurology and the ALS Association.
Multidisciplinary Team
Neurologists: Prof Ammar Al-Chalabi, Prof Christopher Shaw, Dr Cathy Ellis, Dr Jemeen Sreedharan;
Palliative Care: Dr Rachel Burman;
Respiratory Care: Dr Kai Lee (King’s College Hospital), Dr Michelle Ramsay (Lane Fox Unit)
Clinical Care Coordinator: Caty Bailey; Clinical Nurse Specialist: Adrian Broughton; Speech and Language Therapist: Julia Johnson; Dietician: Angeline Brooks; Physiotherapist: Emma Anderson; Occupational Therapist: Eimear O’Hanlon; Volunteer: Beth Birkbeck;
Laboratory and Clinical Research Teams: Theresa Chiwera (Research Nurse), Anna Kulka (Project Manager), Aleksey Shatunov (Genetics), Ashley Jones (Transcriptomics), William Sproviero (Genetics), Sarah Martin (Computer Scientist), Ahmad Al-Khleifat (Structural Genetics), Alfredo Iacoangeli (Bioinformatics), Visiting Posts.
| King’s MND Care and Research Centre | |
|---|---|
| Foundation year | 1990 |
| Director | Professor Ammar Al-Chalabi |
| Principal investigator | Professor Ammar Al-Chalabi |
| Contact information | |
|---|---|
| Address | Kings College London |
| Phone | +44 20 7848 5172 |
| Fax | +44 20 7848 5190 |
| rtuck@nhs.net | |
| Website | Visit the website |
Publications
Find a full list of publications via this link.
- Amyotrophic lateral sclerosis: moving towards a new classification system. Al-Chalabi A, Hardiman O, Kiernan MC, Chiò A, Rix-Brooks B, van den Berg LH. The Lancet. Neurology. 2016; 15(11):1182-94.
- Gene discovery in amyotrophic lateral sclerosis: implications for clinical management. Al-Chalabi A, van den Berg LH, Veldink J. Nature reviews. Neurology. 2017; 13(2):96-104.
- Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. van Rheenen W, Shatunov A, Dekker AM, McLaughlin RL, Diekstra FP, Pulit SL, van der Spek RA, Võsa U, de Jong S, Robinson MR, Yang J, Fogh I, et al, Filosto M, Muller B, Stuit RJ, Blair I, Zhang K, McCann EP, Fifita JA, Nicholson GA, Rowe DB, Pamphlett R, Kiernan MC, Grosskreutz J, Witte OW, Ringer T, Prell T, Stubendorff B, Kurth I, Hübner CA, Leigh PN, Casale F, Chio A, Beghi E, Pupillo E, Tortelli R, Logroscino G, Powell J, Ludolph AC, Weishaupt JH, Robberecht W, Van Damme P, Franke L, Pers TH, Brown RH, Glass JD, Landers JE, Hardiman O, Andersen PM, Corcia P, Vourc’h P, Silani V, Wray NR, Visscher PM, de Bakker PI, van Es MA, Pasterkamp RJ, Lewis CM, Breen G, Al-Chalabi A, van den Berg LH, Veldink JH. Nature genetics. 2016; 48(9):1043-8.
- A clinical tool for predicting survival in ALS. Knibb JA, Keren N, Kulka A, Leigh PN, Martin S, Shaw CE, Tsuda M, Al-Chalabi A. Journal of neurology, neurosurgery, and psychiatry. 2016; 87(12):1361-1367.
- Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. Al-Chalabi A, Calvo A, Chio A, Colville S, Ellis CM, Hardiman O, Heverin M, Howard RS, Huisman MH, Keren N, Leigh PN, Mazzini L, Mora G, Orrell RW, Rooney J, Scott KM, Scotton WJ, Seelen M, Shaw CE, Sidle KS, Swingler R, Tsuda M, Veldink JH, Visser AE, van den Berg LH, Pearce N. he Lancet. Neurology. 2014; 13(11):1108-13.
Restricted information
| Serving population | |
|---|---|
| Serving population | 1.000.000 or more |
| Patient resources | |
|---|---|
| Population based register | Yes |
| Clinic based register | Yes |
| Geographically matched controls | No |
| Number of spinal cord samples | 50 |
| Number of brain samples | 200 |
Banks
| Type | ALS Patients | Controls | Other |
|---|---|---|---|
| DNA Bank | 1700 | 1000 | 0 |
| Research activities | |
|---|---|
| Clinical management research | Yes |
| Neuro epidemiology | Yes |
| Neuro physiology | Yes |
| Neuro imaging | Yes |
| Neuro psychology | Yes |
| Neuro pathology | Yes |
| Genomics | Yes |
| Transcriptomics | Yes |
| Metabolomics | Yes |
Clinical Trials - Industry sponsored
| Name | Type | Patients |
|---|---|---|
| OrionPharma LEVALS (International lead) | OrionPharma LEVALS | |
| Cytokinetics VITALITY-ALS (National lead) | Cytokinetics VITALITY-ALS |
Clinical Trials - Investigator initiated
| Name | Type | Patients |
|---|---|---|
| MIROCALS | MIROCALS | |
| CALL-Me (smartphone app) | CALL-Me (smartphone app) |